prion like protein doppelGenealiases: DOPPEL · DPL · PrPLP · dJ1068H6.4
Q-omics provides the consensus-scored PRND profile across patient tissues and cancer cell-line models. PRND expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRND is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PRND RNA expression shows 11,933 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, KIRC, and BRCA as cancer lineages where PRND shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRND — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRND survival associations across molecular data types. PRND RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRND RNA expression–survival associations across cancer types. High PRND expression shows unfavorable associations in KIRP, BLCA, LGG and THCA, but favorable associations in HNSC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRND RNA expression.
This table summarizes PRND tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRND. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRND shows lower tumor expression in UCEC and higher tumor expression in KIRC, LIHC, HNSC, THCA and ESCA. The KIRC box plot shows higher PRND RNA expression in tumor versus normal tissue (log2 FC = +0.983, t-test p < 0.001).
This table shows molecular features associated with PRND in patient tissues and cancer cell lines. In patient samples, PRND shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, PRND RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
